The study involved a Level I SMART trial for low-back pain, which compared the Intracept procedure to a placebo procedure over 24 months.
Three notable results of the trial:
1. Opioid use was eliminated in 46.4 percent of patients who took opioids at baseline.
2. The number of patients receiving spinal injections for pain was reduced from 57.5 percent to 7.5 percent two years after treatment.
3. The researchers reported no related serious adverse events.
Read the full study here.
More articles on devices:
Stryker sees 80% spike in Mako users in Q1, anticipates further growth: 5 things to know
Stryker aims to make a new spine acquisition in the next 6 months, K2M integration on track
12 devicemakers prepare pitches for judges from Medtronic, DePuy Synthes & more
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
